IL37 and myeloid sarcoma: Recombinant IL-37 has been proposed as a novel therapeutic strategy for MS, since patients, despite the low production of endogenous IL-37, still present the receptor complex IL-1R5//IL-1R8 on their PBMCs and brain lesions (119).